NICE turns down Janssen’s Imbruvica for rare blood cancer
Cost regulators for the NHS in England and Wales have turned down Janssen’s Imbruvica for treating some people with Waldenstrom’s macroglobulinaemia (WM) – a rare type of slow growing non-Hodgkin’s lymphoma.
Read More
